Navigation Links
FDA Cites Challenges of Generic Biotech

A top drug regulator told lawmakers Monday it could be a decade or more before science is available to safely approve generic versions of biotech drugs // in the way the agency approves knockoffs of traditional drugs.

Food and Drug Administration deputy commissioner Janet Woodcock's testimony could benefit companies such as Amgen Inc. and Genentech Inc, which have never faced generic competition in the U.S. for their products, some of the most complex and expensive on the market.

That lack of competition would change under a bill recently introduced by Rep. Henry Waxman, D-Calif. The bill would task FDA with approving knockoff versions of biotech medicines, many of which cost tens of thousands of dollars for a year's supply.

Waxman, who chairs the House Committee on Oversight, helped launch the generic drug industry more than 20 years ago when he co-wrote legislation allowing generic manufacturers such as Barr Pharmaceutical Inc. and Mylan Laboratories Inc to market cheaper versions of traditional drugs after the originals loose patent protection. Waxman's new legislation would give generic drug makers access to an estimated $12 billion worth of biotech patents that have already expired.

Unlike traditional chemical-based pharmaceuticals, biotech pharmaceuticals are made from living cells and proteins. The biotech industry has long argued that because these proteins are more prone to minor differences when mass produced, it will be more difficult for generic drug companies to safely reproduce them.

Woodcock said that while FDA can currently establish the safety between versions of simple protein-based drugs, it will likely "be a stepwise progression over a decade or so," before the agency can scientifically verify that a knockoff version of a complex biotech drug is similar to the original. Woodcock testified before The House oversight committee along with representatives from the drug industry and consumer groups.
Ranking member Tom Davis, R-Virginia, argued that the complexity of biotech drugs makes it essential that would-be generic biotech makers be required to conduct clinical trials of their products.

A vice president from Denmark-based Novo Nordisk, a biotech company that makes diabetes therapies, agreed. Nordisk's Inger Mollerup said that if Congress creates a system to approve cheaper protein-based drugs it should be similar to one already used by the European Union.

Under the EU system, generic biotech companies have to conduct extensive studies to show the safety of their versions. Even after these studies are completed and the product is approved, knockoff biotech drugs are not considered interchangeable with the original product, meaning a patient has to get doctor approval before switching from the original drug to a generic.

Source-Bio-Bio Technology
'"/>




Related medicine news :

1. Ministry Cites Negligence as Cause of Kazakh baby HIV cases
2. Australia Ready to Meet the Challenges of Bird Flu
3. Sexual Health Service Is Under Pressure and Faced With Financial Challenges
4. Abuja Challenges the Government
5. Nurses in South Africa Face Challenges
6. Bangladesh Progressing But Must Yet Face Challenges In Health Sector
7. Fresh Water, HIV Biggest of Indias Six Challenges: Chidambaram
8. New Study Challenges How Regulators Determine Risk
9. Study Challenges Conventional Treatment of Traumatic Brain Injury
10. Generic drug costs remain shackled
11. FDA Approves Indian Generic Drug For AIDS Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... ... the surrounding regions access to insurance assistance and financial planning services, is announcing ... to assist families in the region facing financial crisis. , Matthew 25: Ministries ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Dianne ... the greater Cincinnati metropolitan area, is teaming up with the local chapter of ... children receiving treatment in nearby hospitals. , Ronald McDonald House of Greater Cincinnati, ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... a cosmetic treatment, according to survey data released today by the American ... Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic medical ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized ... the Ethereum blockchain, has released their technical specifications . , 2017 has seen ... little systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects that ... the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 million ... under current law. , More than 20 million Americans have gained health insurance under ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/7/2017)... 2017 Endo International plc (NASDAQ: ... Hon. Joseph R. Goodwin , U.S. District Court ... Virginia , entered a case management order in ... Products Liability Litigation (the "MDL") that includes a provision ... expert disclosures on specific causation within one hundred twenty ...
Breaking Medicine Technology: